Below is an educational, technical answer to a question many patients and clinicians ask. Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team.
What is the success rate of liver tumor ablation?
Reported outcomes for liver tumor ablation vary with tumor size, number, location, and underlying liver function, so a single figure cannot be generalized across patients. Published data indicate that thermal ablation such as RFA and MWA can achieve high rates of local tumor control for small hepatocellular carcinomas in appropriately selected patients. Achieving an adequate ablation margin around the tumor is widely regarded in the literature as important for durable local control. These are population-level observations, and an individual's expected outcome should be discussed with the treating clinician rather than inferred from published averages.
What This Means in Practice
Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes. All INVAMED ablation devices are intended for use by trained clinicians under appropriate image guidance and in accordance with the IFU. Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
Key Considerations
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
Frequently Asked Questions
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
Is the HyperTiss set an ablation device?
INVAMED describes HyperTiss as an intracavitary (intravesical) temperature-therapy set intended for adjunctive use with intravesical chemotherapy in bladder cancer, rather than as a standalone tumor ablation device.
About INVAMED
INVAMED operates a dedicated R&D center (INVAcenter) focused on minimally invasive device development. INVAMED states it maintains a growing portfolio of international patents across its device range.
Clinical and Technical Context
Unlike heat-based methods, the mechanism relies on cold injury, and the choice among cryoablation, RFA, and MWA depends on tumor and patient factors weighed by the clinician. Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone. MWA is frequently discussed for liver and lung tumors, but suitability, applicator selection, and power protocol are determined case by case by the interventional physician. This is an endoscopic energy technique whose indication and parameters are established by the treating urologist rather than by any general rule.
Related on INVAMED
- Oncology Ablation — product category
- Understanding Percutaneous Thermal Ablation Electrodes
- ThermoEdge RFA Platform — Technical Overview
- What is the heat-sink effect in ablation?
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.